Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.

Kathleen E CoreyMatthew J KlebanoffAngela C TramontanoRaymond T ChungChin Hur

Published in: Digestive diseases and sciences (2016)

Screening for NASH may improve liver-related outcomes, but is not cost-effective at present, due to side effects of therapy. As better tolerated treatments for NASH become available, even with modest efficacy, screening for NASH will become cost-effective.

Keyphrases

type diabetes
stem cells
skeletal muscle
bone marrow
mesenchymal stem cells
glycemic control